SYSTEMATIC REVIEW
Published on 29 Jan 2025
Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks
doi 10.3389/fphar.2025.1491990
- 143 views
- Frontiers in Oncology
- Pharmacology of Anti-Cancer Drugs
- Research Topics
- EGFR-TKIs for Lung Cancer Treatment: Development, Application, and Side Effects
EGFR-TKIs for Lung Cancer Treatment: Development, Application, and Side Effects
2,771
Total downloads
9,917
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
CASE REPORT
Accepted on 27 Jan 2025
A patient with EGFR L861Q positive adenosquamous lung carcinoma transforming into large cell neuroendocrine cancer after treatment with Almonertinib --A case report
doi 10.3389/fonc.2025.1453066
CASE REPORT
Accepted on 06 Jan 2025
Almonertinib-induced interstitial lung disease in a NSCLC patient co-harboring EGFR Ex19del mutation and MET de-novo amplification: A case report and literature review
doi 10.3389/fonc.2025.1481244
SYSTEMATIC REVIEW
Published on 23 Dec 2024
Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis
doi 10.3389/fimmu.2024.1512468
- 546 views
CASE REPORT
Published on 17 Dec 2024
A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review
doi 10.3389/fonc.2024.1467722
- 552 views
ORIGINAL RESEARCH
Published on 12 Dec 2024
Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression
doi 10.3389/fonc.2024.1472545
- 334 views
ORIGINAL RESEARCH
Published on 06 Sep 2024
Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study
doi 10.3389/fphar.2024.1444707
- 905 views
CASE REPORT
Published on 21 Aug 2024
Potential therapeutic option for EGFR-mutant small cell lung cancer transformation: a case report and literature review
doi 10.3389/fimmu.2024.1439033
- 1,657 views
ORIGINAL RESEARCH
Published on 25 Jul 2024
Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data
doi 10.3389/fphar.2024.1428158
- 1,076 views
ORIGINAL RESEARCH
Published on 12 Jul 2024
Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer
doi 10.3389/fonc.2024.1431023
- 904 views
MINI REVIEW
Published on 24 Jun 2024
EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring
doi 10.3389/fonc.2024.1426796
- 1,003 views
Published in
Frontiers in Oncology
- Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Pharmacology
- 4.4 impact factor
- 7.8 citescore
Impact
- 9,917Topic views
- 6,203Article views
- 2,771Article downloads